US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Clearmind Medicine, Inc.

0.9488

+0.00890.95%

Post-market: 0.95990.0111+1.17%19:57 EDT

Volume:160.67K

Turnover:153.96K

Market Cap:4.87M

PE:-0.74

High:1.05

Open:0.9400

Low:0.9144

Close:0.9399

Loading ...

Overview Company News Filings

Clearmind Medicine Enrolls First Patient in Study of Potential Alcohol Abuse Treatment

MT Newswires Live

Clearmind Medicine Announces Enrollment of First Patient in Phase I/Iia Clinical Trial for Alcohol Use Disorder Treatment

THOMSON REUTERS

Psychedelic: Clearmind completes clinical site initiations for AUD trial

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

BRIEF-Clearmind Medicine Completes The Initiation Of Its Alcohol Use Disorder Phase I/IIA Clinical Trial At All Current Clinical Sites

Clearmind Medicine Completes the Initiation of Its Alcohol Use Disorder Phase I/Iia Clinical Trial at All Current Clinical Sites

THOMSON REUTERS

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

BRIEF-Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

THOMSON REUTERS

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Clearmind Medicine Launches First U.S. Clinical Site for Its FDA-Approved Clinical Trial to Combat Alcoholism

THOMSON REUTERS

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Clearmind Medicine Starts Phase 1/2a Trial of CMND-100 in Patients With Alcohol Use Disorder

MT Newswires Live

Clearmind Medicine announces U.S. clinical site initiation for CMND-100 trial

Clearmind Medicine Announces First U.S. Clinical Site Initiation for Cmnd-100 Clinical Trial in Patients With Alcohol Use Disorder

THOMSON REUTERS

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Clearmind Launches Its Edc System to Support Its Phase I/Ii Clinical Trial of Its Meai-Based Treatment

THOMSON REUTERS

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CMND/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMND\",,,,,undefined,":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":0.9488,"timestamp":1749240000000,"preClose":0.9399,"halted":0,"volume":160665,"hourTrading":{"tag":"盘后","latestPrice":0.9599,"preClose":0.9488,"latestTime":"19:57 EDT","volume":10961,"amount":10139.8562,"timestamp":1749254266919},"delay":0,"floatShares":4643565,"shares":5134786,"eps":-1.290303,"marketStatus":"Market Closed","change":0.0089,"latestTime":"06-06 16:00:00 EDT","open":0.94,"high":1.05,"low":0.9144,"amount":153955.03513950002,"amplitude":0.144271,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.290303,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":0.9399,"preHourTrading":{"tag":"盘前","latestPrice":0.96,"preClose":0.9399,"latestTime":"09:28 EDT","volume":4080,"amount":3769.232928,"timestamp":1749216481988},"postHourTrading":{"tag":"盘后","latestPrice":0.9599,"preClose":0.9488,"latestTime":"19:57 EDT","volume":10961,"amount":10139.8562,"timestamp":1749254266919},"volumeRatio":0.6396210326010754},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMND\",,,,,undefined,":{"symbol":"CMND","floatShares":4643565,"roa":"-43.89%","roe":"-125.61%","lyrEps":-1.694985,"volumeRatio":0.6396210326010754,"shares":5134786,"dividePrice":0,"high":1.05,"amplitude":0.144271,"preClose":0.9399,"low":0.9144,"week52Low":0.85,"pbRate":"1.71","week52High":2.3,"institutionHeld":0,"latestPrice":0.9488,"eps":-1.290303,"divideRate":0,"volume":160665,"delay":0,"ttmEps":-1.290303,"open":0.94,"prevYearClose":1.38,"prevWeekClose":0.962,"prevMonthClose":0.962,"prevQuarterClose":1.035,"fiveDayClose":0.962,"twentyDayClose":0.977,"sixtyDayClose":1.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMND\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541027724","title":"Clearmind Medicine Enrolls First Patient in Study of Potential Alcohol Abuse Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2541027724","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541027724?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:00","pubTimestamp":1749124856,"startTime":"0","endTime":"0","summary":"Clearmind Medicine  said it has enrolled the first patient for its phase 1/2a clinical trial of CMND-100, an oral drug candidate aimed at treating alcohol use disorder.The trial is aimed at assessing the safety, tolerability, and pharmacokinetic effects of CMND-100 in potentially reducing alcohol cravings and consumption, the clinical-stage company said.Shares of the company were up 6% in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2541022024","title":"Clearmind Medicine Announces Enrollment of First Patient in Phase I/Iia Clinical Trial for Alcohol Use Disorder Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2541022024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541022024?lang=en_us&edition=fundamental","pubTime":"2025-06-05 19:32","pubTimestamp":1749123120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nTUA8T8C7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IXHL","MIRA","DRUG","BK4202","MYCOF","ENVB","BK4539","PBM","SPRC","CYBN","GHRS","MNMD","NUMIF","BK4547","ALID","OPTHF","SILO","CMPS","RLMD","BETRF","MDXXF","ENTBF","FLHLF","NRXP","AGNPF","BK4168","BK4007","SEEL","ATAI","SNPX","BK4139","PHRRF","RVVTF","PSYGF","QNTM","KTTA","CMND"],"gpt_icon":0},{"id":"2530184089","title":"SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2530184089","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530184089?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:59","pubTimestamp":1745582340,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 25, 2025  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc.  has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.Eating disorders are serious mental health conditions that negatively impact an individual’s health, emotions, and ability to perform daily functions. Eating disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders. According to recent studies, up to 70 million people globally are affected by eating disorders, with significant increases observed among children and adolescents. Global eating disorder prevalence increased from 3.4% to 7.8% between 2000 and 2018.Common shares of Clearmi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-clearmind-collaboration-leads-filing-115900685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMND","BK4007","SPRC"],"gpt_icon":0},{"id":"2530847021","title":"Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2530847021","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530847021?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:55","pubTimestamp":1745582100,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 25, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.Eating disorders are serious mental health conditions that negatively impact an individual’s health, emotions, and ability to perform daily functions. Eating disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders. According to recent studies, up to 70 million people globally are affected by eating disorders, with significant increases observed among children and adolescents. Global eating disorder prevalence increased from 3.4% to 7.8% between 2000 and 2018.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-files-international-patent-115500327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2529500545","title":"BRIEF-Clearmind Medicine Completes The Initiation Of Its Alcohol Use Disorder Phase I/IIA Clinical Trial At All Current Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2529500545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529500545?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:37","pubTimestamp":1745411835,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Completes The Initiation Of Its Alcohol Use Disorder Phase I/IIA Clinical Trial At All Current Clinical SitesApril 23 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDIC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA17MKZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2529071395","title":"Clearmind Medicine Completes the Initiation of Its Alcohol Use Disorder Phase I/Iia Clinical Trial at All Current Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2529071395","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529071395?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:25","pubTimestamp":1745411100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA17MKZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2529030637","title":"Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2529030637","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529030637?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:25","pubTimestamp":1745411100,"startTime":"0","endTime":"0","summary":"The Company is now preparing for the enrollment of the first patient to receive Clearmind’s innovative treatment as part of the trial. Vancouver, Canada, April 23, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the initiation of its U.S. clinical trial site at the Yale School of Medicine’s Department of Psychiatry. With this initiation, the Company has now activated all planned sites for its clinical trial for its Phase I/IIa clinical trial in Alcohol Use Disorder  and can begin patient enrollment .Clearmind has completed all necessary preparations for the clinical trial, including obtaining Investigational New Drug  approval from the U.S. Food and Drug Administration  to start the Phase I/IIa clinical trial, Institutional Review Board  approvals from each clinical site, launch of its Electronic Data Capture  system to supp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-completes-initiation-alcohol-122500446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMND","EDC","BK4007"],"gpt_icon":0},{"id":"2529801200","title":"Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts","url":"https://stock-news.laohu8.com/highlight/detail?id=2529801200","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529801200?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:15","pubTimestamp":1745241300,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 21, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled \"Gazing Through the Crystal Ball.\" The event is scheduled for May 21, 2025, at 12:00 PM ET  and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates.Rick Doblin, PhD – Founder and President of the Multidisciplinary Association for Psychedelic Studies . A trailblazer in psychedelic-assisted therapy, Dr. Doblin has dedicated his career to establishing safe, legal, and ethical uses of psychedelics through rigorous scientific research.Robin Carhart-Harris, PhD – Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco . Dr. Carhart-Har","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-host-live-webinar-131500592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4585","BK4588","BK4218","CMND","HST","BK4007","BK4023","MAPS"],"gpt_icon":0},{"id":"2528371412","title":"BRIEF-Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior","url":"https://stock-news.laohu8.com/highlight/detail?id=2528371412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528371412?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:44","pubTimestamp":1744893896,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge BehaviorApril 17 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE RECEIVES NOTICE OF ALLOWANCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2528713474","title":"Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior","url":"https://stock-news.laohu8.com/highlight/detail?id=2528713474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528713474?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:38","pubTimestamp":1744889886,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2528716108","title":"Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior","url":"https://stock-news.laohu8.com/highlight/detail?id=2528716108","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528716108?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:38","pubTimestamp":1744889880,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 17, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to its MEAI treatment for binge behavior.This new US patent provides additional intellectual property protection for the Company’s novel MEAI- based treatment in this indication and further strengthens Clearmind’s intellectual property portfolio.Dr. Adi Zuloff-Shani, CEO of Clearmind, commented: “This Notice of Allowance further strengthens our unique position in the space and growing intellectual property portfolio and reinforces the potential of our robust MEAI program. Securing foundational patent protection is a vital step in supporting our future success and in driving the development of next-generation psychedelic-derived therapeutics with the potential","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-receives-notice-allowance-113800073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UBCP","CMND","BK4007","BK4211"],"gpt_icon":0},{"id":"2527321161","title":"Clearmind Medicine Launches First U.S. Clinical Site for Its FDA-Approved Clinical Trial to Combat Alcoholism","url":"https://stock-news.laohu8.com/highlight/detail?id=2527321161","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527321161?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:40","pubTimestamp":1744807200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA31MMR5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2527028247","title":"Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism","url":"https://stock-news.laohu8.com/highlight/detail?id=2527028247","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527028247?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:40","pubTimestamp":1744807200,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 16, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind’s innovative treatment, CMND-100, in Alcohol Use Disorder  patients. This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company’s mission to provide innovative solutions for addictions, weight loss and mental health disorders such as depression and anxiety.Alcohol Use Disorder remains a major global health challenge, affecting millions of individuals worldwide. The disorder is linked to severe health complications, inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-launches-first-u-124000936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2526597372","title":"Clearmind Medicine Starts Phase 1/2a Trial of CMND-100 in Patients With Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2526597372","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526597372?lang=en_us&edition=fundamental","pubTime":"2025-04-10 23:27","pubTimestamp":1744298820,"startTime":"0","endTime":"0","summary":"Clearmind Medicine  said Thursday that it has started a phase 1/2a clinical trial of CMND-100 in patients will alcohol use disorder at the Johns Hopkins University School of Medicine, the company's first clinical site in the US.The biotechnology company said the trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100 and will also include preliminary efficacy evaluations to assess its potential in reducing alcohol cravings and consumption.Price: 0.95, Change: -0.03, Percent Change: -3.06","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2526569354","title":"Clearmind Medicine announces U.S. clinical site initiation for CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526569354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526569354?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:31","pubTimestamp":1744288310,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-u-s-clinical-site-initiation-for-cmnd-100-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-u-s-clinical-site-initiation-for-cmnd-100-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2526794565","title":"Clearmind Medicine Announces First U.S. Clinical Site Initiation for Cmnd-100 Clinical Trial in Patients With Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2526794565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526794565?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:25","pubTimestamp":1744287900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA7KQSDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2526558569","title":"Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2526558569","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526558569?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:25","pubTimestamp":1744287900,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 10, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind’s innovative treatment, CMND-100, in Alcohol Use Disorder  patients. This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company’s mission to provide innovative solutions for addictions, weight loss and mental health disorders such as depression and anxiety.Alcohol Use Disorder remains a major global health challenge, affecting millions of individuals worldwide. The disorder is linked to severe health complications, i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-announces-first-u-122500938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2524118106","title":"Clearmind Launches Its Edc System to Support Its Phase I/Ii Clinical Trial of Its Meai-Based Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118106?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:15","pubTimestamp":1743509700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA8HBYJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","MYCOF","PBM","ENTBF","AGNPF","CYBN","BETRF","DRUG","RVVTF","BK4539","NUMIF","SPRC","BK4007","SEEL","RLMD","CMPS","PHRRF","CMND","SNPX","BK4547","MIRA","ALID","GHRS","PSYGF","MNMD","QNTM","ATAI","SILO","MDXXF","IXHL","BK4139","NRXP","OPTHF","KTTA","BK4168","FLHLF"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMND\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-11-28","symbol":"CMND","defaultRemindTime":1701181800000,"type":"split","dateTimestamp":1701147600000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CMND\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CMND\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CMND","date":"2025-06-06","current":-0.973316,"percent":0.634365,"low":-85.590719,"twenty":-19.430851,"median":-1.337978,"eighty":-0.550857,"high":-0.132425,"avg":-10.9597,"sd":19.330396,"marketCap":4826185},"quantilePoints":[{"date":"2020-06-12","current":-9.227851,"twenty":-61.834695,"median":-5.926622,"eighty":-5.327909,"marketCap":1483232.42},{"date":"2020-06-19","current":-9.227851,"twenty":-61.834695,"median":-5.926622,"eighty":-5.327909,"marketCap":1485830.79},{"date":"2020-06-26","current":-15.147663,"twenty":-61.834695,"median":-6.222948,"eighty":-5.327909,"marketCap":1472759.44},{"date":"2020-07-02","current":-15.147663,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":1484325.27},{"date":"2020-07-10","current":-15.147663,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":1484630.94},{"date":"2020-07-17","current":-30.295333,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2973921.4},{"date":"2020-07-24","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2650378.93},{"date":"2020-07-31","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2655543.86},{"date":"2020-08-07","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2659296.56},{"date":"2020-08-14","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2683453.93},{"date":"2020-08-21","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2695636.65},{"date":"2020-08-28","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2713715.75},{"date":"2020-09-04","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2710530.81},{"date":"2020-09-11","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2698172.45},{"date":"2020-09-18","current":-26.688751,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2700364.44},{"date":"2020-09-25","current":-19.430851,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2652137.89},{"date":"2020-10-02","current":-19.430851,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2672966.88},{"date":"2020-10-09","current":-19.430851,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2708177.93},{"date":"2020-10-16","current":-19.430851,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2697619.9},{"date":"2020-10-23","current":-19.430851,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2705582.14},{"date":"2020-10-30","current":-19.430851,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2672826.27},{"date":"2020-11-06","current":-19.430851,"twenty":-61.834695,"median":-9.227851,"eighty":-5.327909,"marketCap":2729585.8},{"date":"2020-11-13","current":-19.430851,"twenty":-58.731697,"median":-9.227851,"eighty":-5.327909,"marketCap":2702313.58},{"date":"2020-11-20","current":-19.430851,"twenty":-49.917404,"median":-9.227851,"eighty":-5.327909,"marketCap":2722231.75},{"date":"2020-11-27","current":-19.430851,"twenty":-43.261737,"median":-9.227851,"eighty":-5.327909,"marketCap":2739910.48},{"date":"2020-12-04","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2777635.21},{"date":"2020-12-11","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2786514.1},{"date":"2020-12-18","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2782611.72},{"date":"2020-12-24","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2773130.45},{"date":"2020-12-31","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2791259.61},{"date":"2021-01-08","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2797670.85},{"date":"2021-01-15","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2792684.23},{"date":"2021-01-22","current":-19.430851,"twenty":-41.597849,"median":-9.227851,"eighty":-5.327909,"marketCap":2794856.82},{"date":"2021-01-29","current":-19.430851,"twenty":-41.597849,"median":-12.187757,"eighty":-5.327909,"marketCap":2782481.11},{"date":"2021-02-05","current":-19.430851,"twenty":-41.597849,"median":-15.147663,"eighty":-5.327909,"marketCap":2783787.82},{"date":"2021-02-12","current":-19.430851,"twenty":-41.597849,"median":-15.147663,"eighty":-5.327909,"marketCap":2799961.42},{"date":"2021-02-19","current":-19.430851,"twenty":-39.933931,"median":-15.147663,"eighty":-5.327909,"marketCap":2822403.07},{"date":"2021-02-26","current":-19.430851,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":2800424.4},{"date":"2021-03-05","current":-8.613576,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":2802476.56},{"date":"2021-03-12","current":-8.613576,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":2848351.83},{"date":"2021-03-19","current":-8.613576,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":2843228.53},{"date":"2021-03-26","current":-8.613576,"twenty":-37.438053,"median":-9.227851,"eighty":-5.327909,"marketCap":2828395.91},{"date":"2021-04-01","current":-11.587771,"twenty":-37.438053,"median":-9.227851,"eighty":-5.327909,"marketCap":2829836.18},{"date":"2021-04-09","current":-11.587771,"twenty":-37.438053,"median":-11.587771,"eighty":-5.327909,"marketCap":2832089.53},{"date":"2021-04-16","current":-11.587771,"twenty":-37.438053,"median":-11.587771,"eighty":-5.327909,"marketCap":2845184.59},{"date":"2021-04-23","current":-17.615217,"twenty":-37.438053,"median":-11.587771,"eighty":-5.327909,"marketCap":4326958.35},{"date":"2021-04-30","current":-17.615217,"twenty":-37.438053,"median":-11.587771,"eighty":-5.327909,"marketCap":4388776.06},{"date":"2021-05-07","current":-17.615217,"twenty":-37.438053,"median":-13.367717,"eighty":-5.327909,"marketCap":4452312.37},{"date":"2021-05-14","current":-17.615217,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":4466989.71},{"date":"2021-05-21","current":-17.615217,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":4486524.55},{"date":"2021-05-28","current":-78.078262,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":19823707.07},{"date":"2021-06-04","current":-75.221742,"twenty":-37.438053,"median":-15.147663,"eighty":-5.327909,"marketCap":19088186.32},{"date":"2021-06-11","current":-71.413047,"twenty":-37.438053,"median":-16.38144,"eighty":-5.327909,"marketCap":18026757.96},{"date":"2021-06-18","current":-69.508697,"twenty":-41.597849,"median":-17.615217,"eighty":-5.327909,"marketCap":17101728.27},{"date":"2021-06-25","current":-77.126088,"twenty":-41.597849,"median":-17.615217,"eighty":-5.327909,"marketCap":19258243.57},{"date":"2021-07-02","current":-77.809745,"twenty":-41.597849,"median":-17.615217,"eighty":-5.327909,"marketCap":27345681.85},{"date":"2021-07-09","current":-81.267955,"twenty":-45.757607,"median":-17.615217,"eighty":-5.327909,"marketCap":28278833.84},{"date":"2021-07-16","current":-82.132509,"twenty":-57.232721,"median":-17.615217,"eighty":-5.327909,"marketCap":28316450.35},{"date":"2021-07-23","current":-82.99706,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":28633395.33},{"date":"2021-07-30","current":-84.726165,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":29489162.42},{"date":"2021-08-06","current":-83.861681,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":28960917.86},{"date":"2021-08-13","current":-80.403466,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":27911893.15},{"date":"2021-08-20","current":-61.38329,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":20727360.57},{"date":"2021-08-27","current":-66.570612,"twenty":-61.834695,"median":-18.523034,"eighty":-5.327909,"marketCap":22871673.05},{"date":"2021-09-03","current":-77.809807,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":26985610.07},{"date":"2021-09-10","current":-70.893378,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":24346632.12},{"date":"2021-09-17","current":-71.757932,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":24430331.48},{"date":"2021-09-24","current":-73.487039,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":25125635.9},{"date":"2021-10-01","current":-18.935815,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":24276713.03},{"date":"2021-10-08","current":-18.012117,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":23471549.77},{"date":"2021-10-15","current":-18.012117,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":23660527.38},{"date":"2021-10-22","current":-17.781192,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":23366442.66},{"date":"2021-10-29","current":-16.626569,"twenty":-61.834695,"median":-19.430851,"eighty":-5.327909,"marketCap":21791515.03},{"date":"2021-11-05","current":-17.319343,"twenty":-61.834695,"median":-18.935815,"eighty":-5.327909,"marketCap":22614497.39},{"date":"2021-11-12","current":-16.16472,"twenty":-61.834695,"median":-18.473966,"eighty":-5.327909,"marketCap":20907283.62},{"date":"2021-11-19","current":-15.933796,"twenty":-61.834695,"median":-18.243042,"eighty":-5.327909,"marketCap":20493935.46},{"date":"2021-11-26","current":-17.319343,"twenty":-61.834695,"median":-18.243042,"eighty":-5.327909,"marketCap":22007930.87},{"date":"2021-12-03","current":-16.16472,"twenty":-61.834695,"median":-18.012117,"eighty":-5.327909,"marketCap":20516830.56},{"date":"2021-12-10","current":-15.933796,"twenty":-61.834695,"median":-18.012117,"eighty":-5.327909,"marketCap":20363701.64},{"date":"2021-12-17","current":-14.548248,"twenty":-61.834695,"median":-18.012117,"eighty":-5.327909,"marketCap":18448575.82},{"date":"2021-12-23","current":-13.393625,"twenty":-61.834695,"median":-17.781192,"eighty":-5.327909,"marketCap":16986524.41},{"date":"2021-12-31","current":-13.393625,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":17198471.74},{"date":"2022-01-07","current":-12.700852,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":16298591.95},{"date":"2022-01-14","current":-12.239002,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":15851627.15},{"date":"2022-01-21","current":-10.853455,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":14077636.85},{"date":"2022-01-28","current":-12.931776,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":16468260.15},{"date":"2022-02-04","current":-14.548248,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":18518085.11},{"date":"2022-02-11","current":-14.317323,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":18343985.21},{"date":"2022-02-18","current":-14.317323,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":18253458.39},{"date":"2022-02-25","current":-13.393625,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":17082383.51},{"date":"2022-03-04","current":-4.943147,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":14402278.55},{"date":"2022-03-11","current":-4.741385,"twenty":-61.834695,"median":-17.615217,"eighty":-5.327909,"marketCap":13870054.34},{"date":"2022-03-18","current":-4.489184,"twenty":-61.834695,"median":-17.582743,"eighty":-5.327909,"marketCap":13226105.9},{"date":"2022-03-25","current":-2.663476,"twenty":-61.834695,"median":-17.550268,"eighty":-5.327909,"marketCap":12172123.95},{"date":"2022-04-01","current":-2.696359,"twenty":-61.834695,"median":-17.319343,"eighty":-5.327909,"marketCap":12315499.88},{"date":"2022-04-08","current":-3.090948,"twenty":-61.834695,"median":-17.319343,"eighty":-5.327909,"marketCap":14024131.41},{"date":"2022-04-14","current":-2.433299,"twenty":-61.834695,"median":-17.088418,"eighty":-5.327909,"marketCap":11016821.23},{"date":"2022-04-22","current":-2.30177,"twenty":-61.834695,"median":-16.857494,"eighty":-5.327909,"marketCap":10351738.45},{"date":"2022-04-29","current":-2.564829,"twenty":-61.834695,"median":-16.857494,"eighty":-5.327909,"marketCap":11431112.19},{"date":"2022-05-06","current":-2.531947,"twenty":-61.834695,"median":-16.511107,"eighty":-5.327909,"marketCap":11240443.79},{"date":"2022-05-13","current":-2.433299,"twenty":-61.834695,"median":-16.16472,"eighty":-5.327909,"marketCap":10747956.2},{"date":"2022-05-20","current":-2.466182,"twenty":-61.834695,"median":-16.16472,"eighty":-5.327909,"marketCap":10972362.04},{"date":"2022-05-27","current":-2.334652,"twenty":-61.834695,"median":-16.16472,"eighty":-5.327909,"marketCap":10462796.86},{"date":"2022-06-03","current":-2.400417,"twenty":-61.834695,"median":-15.933796,"eighty":-5.327909,"marketCap":10896966.45},{"date":"2022-06-10","current":-2.30177,"twenty":-61.834695,"median":-15.702871,"eighty":-5.327909,"marketCap":10273199.15},{"date":"2022-06-17","current":-2.400417,"twenty":-61.834695,"median":-15.471947,"eighty":-5.327909,"marketCap":10503138.41},{"date":"2022-06-24","current":-2.367534,"twenty":-61.744414,"median":-15.471947,"eighty":-5.327909,"marketCap":10469452.66},{"date":"2022-07-01","current":-1.560974,"twenty":-60.553176,"median":-15.147663,"eighty":-5.327909,"marketCap":10729626.02},{"date":"2022-07-08","current":-1.560974,"twenty":-57.232721,"median":-15.147663,"eighty":-5.327909,"marketCap":10710469.08},{"date":"2022-07-15","current":-1.605574,"twenty":-57.232721,"median":-15.147663,"eighty":-5.327909,"marketCap":10950633.46},{"date":"2022-07-22","current":-1.516375,"twenty":-57.130437,"median":-15.147663,"eighty":-5.327909,"marketCap":10468944.81},{"date":"2022-07-29","current":-1.427176,"twenty":-56.195971,"median":-15.147663,"eighty":-5.327909,"marketCap":9885259.74},{"date":"2022-08-05","current":-1.471776,"twenty":-55.226088,"median":-14.779173,"eighty":-5.327909,"marketCap":10092669.27},{"date":"2022-08-12","current":-1.427176,"twenty":-54.0772,"median":-14.548248,"eighty":-5.327909,"marketCap":9901792.86},{"date":"2022-08-19","current":-1.427176,"twenty":-43.677709,"median":-14.317323,"eighty":-5.327909,"marketCap":9745576.64},{"date":"2022-08-26","current":-1.382577,"twenty":-41.597849,"median":-14.317323,"eighty":-5.327909,"marketCap":9442770.76},{"date":"2022-09-02","current":-1.271079,"twenty":-41.597849,"median":-14.086399,"eighty":-5.327909,"marketCap":8615042.98},{"date":"2022-09-09","current":-1.427176,"twenty":-41.597849,"median":-14.086399,"eighty":-5.135307,"marketCap":9711214.67},{"date":"2022-09-16","current":-1.360278,"twenty":-41.597849,"median":-13.855475,"eighty":-5.135307,"marketCap":9096403.07},{"date":"2022-09-23","current":-1.248779,"twenty":-41.597849,"median":-13.62455,"eighty":-5.135307,"marketCap":8172150.47},{"date":"2022-09-30","current":-0.929266,"twenty":-41.597849,"median":-13.393625,"eighty":-5.135307,"marketCap":6512507.37},{"date":"2022-10-07","current":-1.087585,"twenty":-41.597849,"median":-13.393625,"eighty":-5.074202,"marketCap":7646662.48},{"date":"2022-10-14","current":-1.080702,"twenty":-41.597849,"median":-13.393625,"eighty":-5.074202,"marketCap":7496705.29},{"date":"2022-10-21","current":-1.049293,"twenty":-41.597849,"median":-13.278163,"eighty":-5.074202,"marketCap":7357917.44},{"date":"2022-10-28","current":-1.165881,"twenty":-41.597849,"median":-13.162701,"eighty":-5.074202,"marketCap":8234273.61},{"date":"2022-11-04","current":-1.08907,"twenty":-41.597849,"median":-13.162701,"eighty":-5.074202,"marketCap":7753472.39},{"date":"2022-11-11","current":-1.082212,"twenty":-38.270012,"median":-12.931776,"eighty":-5.074202,"marketCap":7833552.75},{"date":"2022-11-18","current":-1.935818,"twenty":-37.438053,"median":-12.700852,"eighty":-5.074202,"marketCap":13927482.09},{"date":"2022-11-25","current":-1.650458,"twenty":-37.438053,"median":-12.585389,"eighty":-5.074202,"marketCap":11873272.72},{"date":"2022-12-02","current":-1.27255,"twenty":-37.438053,"median":-12.008078,"eighty":-5.074202,"marketCap":9091614.07},{"date":"2022-12-09","current":-1.079739,"twenty":-37.438053,"median":-11.682462,"eighty":-4.943147,"marketCap":7625598.02},{"date":"2022-12-16","current":-1.40109,"twenty":-37.438053,"median":-11.587771,"eighty":-4.791826,"marketCap":9845331.19},{"date":"2022-12-23","current":-1.375382,"twenty":-37.438053,"median":-11.587771,"eighty":-4.741294,"marketCap":9740512.57},{"date":"2022-12-30","current":-1.141438,"twenty":-37.438053,"median":-11.587771,"eighty":-4.741294,"marketCap":8114893.38},{"date":"2023-01-06","current":-1.118301,"twenty":-37.438053,"median":-11.587771,"eighty":-4.539624,"marketCap":7989125.08},{"date":"2023-01-13","current":-1.62475,"twenty":-37.438053,"median":-11.587771,"eighty":-4.186477,"marketCap":11656520.47},{"date":"2023-01-20","current":-1.568192,"twenty":-37.438053,"median":-10.853455,"eighty":-4.136102,"marketCap":11253776.1},{"date":"2023-01-27","current":-1.33682,"twenty":-37.438053,"median":-9.227851,"eighty":-4.059359,"marketCap":9661985.46},{"date":"2023-02-03","current":-1.332642,"twenty":-37.438053,"median":-9.227851,"eighty":-4.059359,"marketCap":9371651.68},{"date":"2023-02-10","current":-1.393097,"twenty":-37.438053,"median":-9.227851,"eighty":-4.059359,"marketCap":9812413.93},{"date":"2023-02-17","current":-1.272187,"twenty":-37.438053,"median":-9.227851,"eighty":-4.059359,"marketCap":8867258.2},{"date":"2023-02-24","current":-1.240431,"twenty":-37.438053,"median":-9.227851,"eighty":-4.059359,"marketCap":8572078.87},{"date":"2023-03-03","current":-1.10085,"twenty":-37.438053,"median":-9.227851,"eighty":-3.551938,"marketCap":7606207.65},{"date":"2023-03-10","current":-1.198293,"twenty":-37.438053,"median":-9.227851,"eighty":-3.45974,"marketCap":8185550.86},{"date":"2023-03-17","current":-1.120516,"twenty":-37.438053,"median":-9.227851,"eighty":-2.755547,"marketCap":7980631.72},{"date":"2023-03-24","current":-0.916786,"twenty":-37.438053,"median":-9.227851,"eighty":-2.696359,"marketCap":6519731.67},{"date":"2023-03-31","current":-0.417647,"twenty":-37.438053,"median":-9.227851,"eighty":-2.624017,"marketCap":3018701.27},{"date":"2023-04-06","current":-0.132425,"twenty":-37.438053,"median":-9.227851,"eighty":-2.584558,"marketCap":960449.73},{"date":"2023-04-14","current":-0.500779,"twenty":-37.438053,"median":-9.227851,"eighty":-2.531947,"marketCap":3666478.25},{"date":"2023-04-21","current":-0.622397,"twenty":-37.438053,"median":-9.227851,"eighty":-2.499064,"marketCap":4520895.91},{"date":"2023-04-28","current":-0.579473,"twenty":-37.438053,"median":-9.227851,"eighty":-2.453029,"marketCap":4166925.01},{"date":"2023-05-05","current":-0.550857,"twenty":-37.438053,"median":-9.227851,"eighty":-2.433299,"marketCap":3966371.91},{"date":"2023-05-12","current":-0.558011,"twenty":-37.438053,"median":-9.227851,"eighty":-2.433299,"marketCap":4046484.45},{"date":"2023-05-19","current":-0.572319,"twenty":-37.438053,"median":-9.227851,"eighty":-2.400417,"marketCap":4145445.66},{"date":"2023-05-26","current":-0.58694,"twenty":-37.438053,"median":-9.227851,"eighty":-2.367534,"marketCap":4210059.56},{"date":"2023-06-02","current":-0.550709,"twenty":-37.438053,"median":-9.227851,"eighty":-2.367534,"marketCap":3999105.96},{"date":"2023-06-09","current":-0.514478,"twenty":-34.942175,"median":-9.227851,"eighty":-2.321499,"marketCap":3767591.98},{"date":"2023-06-16","current":-0.531091,"twenty":-33.278257,"median":-9.227851,"eighty":-2.30177,"marketCap":3748293.76},{"date":"2023-06-23","current":-0.458354,"twenty":-33.278257,"median":-9.227851,"eighty":-2.28204,"marketCap":3234938.84},{"date":"2023-06-30","current":-0.478478,"twenty":-30.295333,"median":-9.227851,"eighty":-2.043589,"marketCap":3376966.22},{"date":"2023-07-07","current":-0.436578,"twenty":-26.688751,"median":-9.227851,"eighty":-1.802136,"marketCap":3081249.21},{"date":"2023-07-14","current":-0.436972,"twenty":-26.688751,"median":-8.613576,"eighty":-1.651163,"marketCap":3084034.14},{"date":"2023-07-21","current":-0.43717,"twenty":-26.688751,"median":-8.613576,"eighty":-1.562418,"marketCap":3085429.18},{"date":"2023-07-28","current":-0.458608,"twenty":-26.688751,"median":-8.613576,"eighty":-1.560974,"marketCap":3236727.75},{"date":"2023-08-04","current":-0.483799,"twenty":-26.688751,"median":-8.613576,"eighty":-1.558522,"marketCap":3414522.56},{"date":"2023-08-11","current":-0.383836,"twenty":-26.688751,"median":-6.222948,"eighty":-1.516375,"marketCap":2709008.42},{"date":"2023-08-18","current":-0.372906,"twenty":-26.688751,"median":-5.926622,"eighty":-1.471776,"marketCap":2631871.39},{"date":"2023-08-25","current":-0.39406,"twenty":-26.688751,"median":-5.926622,"eighty":-1.471776,"marketCap":2781166.24},{"date":"2023-09-01","current":-0.447028,"twenty":-26.688751,"median":-5.926622,"eighty":-1.427176,"marketCap":3155002.59},{"date":"2023-09-08","current":-0.442472,"twenty":-19.813329,"median":-5.926622,"eighty":-1.427176,"marketCap":3122844.46},{"date":"2023-09-15","current":-0.187109,"twenty":-19.430851,"median":-5.926622,"eighty":-1.427176,"marketCap":1320569.3},{"date":"2023-09-22","current":-0.388305,"twenty":-19.430851,"median":-5.926622,"eighty":-1.427176,"marketCap":2475737.22},{"date":"2023-09-29","current":-0.315336,"twenty":-19.430851,"median":-5.926622,"eighty":-1.415486,"marketCap":2010507.36},{"date":"2023-10-06","current":-0.365327,"twenty":-19.430851,"median":-5.926622,"eighty":-1.395726,"marketCap":2329231.67},{"date":"2023-10-13","current":-0.367265,"twenty":-19.430851,"median":-5.926622,"eighty":-1.382577,"marketCap":2341589.46},{"date":"2023-10-20","current":-0.334674,"twenty":-19.430851,"median":-5.926622,"eighty":-1.368527,"marketCap":2133796.18},{"date":"2023-10-27","current":-0.290523,"twenty":-19.430851,"median":-5.926622,"eighty":-1.366813,"marketCap":1852300.65},{"date":"2023-11-03","current":-0.316281,"twenty":-19.430851,"median":-5.926622,"eighty":-1.360278,"marketCap":2016523.46},{"date":"2023-11-10","current":-0.325261,"twenty":-19.430851,"median":-5.390754,"eighty":-1.337978,"marketCap":2073784.82},{"date":"2023-11-17","current":-0.300361,"twenty":-19.430851,"median":-5.330934,"eighty":-1.337515,"marketCap":1915028.46},{"date":"2023-11-24","current":-0.302508,"twenty":-19.430851,"median":-5.327909,"eighty":-1.335149,"marketCap":1928712.73},{"date":"2023-12-01","current":-0.350938,"twenty":-19.430851,"median":-5.327909,"eighty":-1.296306,"marketCap":2237493.37},{"date":"2023-12-08","current":-0.980569,"twenty":-19.430851,"median":-5.327909,"eighty":-1.274244,"marketCap":6251864.25},{"date":"2023-12-15","current":-0.736628,"twenty":-19.430851,"median":-5.327909,"eighty":-1.271301,"marketCap":4696557.28},{"date":"2023-12-22","current":-0.812759,"twenty":-19.430851,"median":-5.327909,"eighty":-1.259672,"marketCap":5181946.56},{"date":"2023-12-29","current":-0.682126,"twenty":-19.430851,"median":-5.327909,"eighty":-1.237797,"marketCap":4349066.88},{"date":"2024-01-05","current":-0.630384,"twenty":-19.430851,"median":-5.327909,"eighty":-1.211461,"marketCap":4019166.25},{"date":"2024-01-12","current":-0.436686,"twenty":-19.430851,"median":-5.327909,"eighty":-1.179486,"marketCap":2784200.42},{"date":"2024-01-19","current":-0.561866,"twenty":-19.430851,"median":-5.327909,"eighty":-1.15795,"marketCap":3582314.16},{"date":"2024-01-26","current":-0.716167,"twenty":-19.430851,"median":-5.327909,"eighty":-1.132962,"marketCap":4566100.74},{"date":"2024-02-02","current":-0.652747,"twenty":-19.430851,"median":-5.327909,"eighty":-1.116775,"marketCap":5627224.65},{"date":"2024-02-09","current":-0.504935,"twenty":-19.430851,"median":-5.327909,"eighty":-1.1005,"marketCap":4352964.23},{"date":"2024-02-16","current":-0.519849,"twenty":-19.430851,"median":-5.327909,"eighty":-1.096168,"marketCap":4481532.37},{"date":"2024-02-23","current":-0.672729,"twenty":-18.473966,"median":-5.327909,"eighty":-1.087585,"marketCap":5799482.19},{"date":"2024-03-01","current":-0.54179,"twenty":-18.473966,"median":-5.327909,"eighty":-1.08191,"marketCap":4670679.77},{"date":"2024-03-08","current":-0.505134,"twenty":-18.473966,"median":-5.327909,"eighty":-1.079739,"marketCap":4354677.58},{"date":"2024-03-15","current":-0.435211,"twenty":-18.473966,"median":-5.327909,"eighty":-1.064778,"marketCap":3751886.19},{"date":"2024-03-22","current":-0.499967,"twenty":-18.473966,"median":-5.327909,"eighty":-1.046318,"marketCap":4044318},{"date":"2024-03-28","current":-0.471743,"twenty":-18.473966,"median":-5.327909,"eighty":-0.975962,"marketCap":3816009},{"date":"2024-04-05","current":-0.463679,"twenty":-18.473966,"median":-5.327909,"eighty":-0.890377,"marketCap":3750779},{"date":"2024-04-12","current":-0.516095,"twenty":-18.473966,"median":-5.327909,"eighty":-0.810049,"marketCap":4174780},{"date":"2024-04-19","current":-0.475009,"twenty":-18.473966,"median":-5.327909,"eighty":-0.7392,"marketCap":3842428},{"date":"2024-04-26","current":-0.483839,"twenty":-18.473966,"median":-5.327909,"eighty":-0.711567,"marketCap":3913856},{"date":"2024-05-03","current":-0.471784,"twenty":-18.473966,"median":-5.327909,"eighty":-0.652729,"marketCap":3816336},{"date":"2024-05-10","current":-0.604799,"twenty":-18.473966,"median":-5.327909,"eighty":-0.644215,"marketCap":4892320},{"date":"2024-05-17","current":-0.520127,"twenty":-18.473966,"median":-5.327909,"eighty":-0.61393,"marketCap":4207395},{"date":"2024-05-24","current":-0.453599,"twenty":-18.473966,"median":-5.327909,"eighty":-0.600881,"marketCap":3669240},{"date":"2024-05-31","current":-0.459647,"twenty":-18.473966,"median":-5.327909,"eighty":-0.594105,"marketCap":3718163},{"date":"2024-06-07","current":-0.420053,"twenty":-18.473966,"median":-5.109555,"eighty":-0.586092,"marketCap":3397879},{"date":"2024-06-14","current":-0.435455,"twenty":-18.473966,"median":-5.074202,"eighty":-0.577013,"marketCap":3522470},{"date":"2024-06-21","current":-0.612279,"twenty":-18.473966,"median":-5.074202,"eighty":-0.572319,"marketCap":4237588},{"date":"2024-06-28","current":-0.64098,"twenty":-18.566336,"median":-5.074202,"eighty":-0.570751,"marketCap":4436225},{"date":"2024-07-05","current":-0.727082,"twenty":-18.566336,"median":-5.074202,"eighty":-0.570751,"marketCap":5032136},{"date":"2024-07-12","current":-0.770133,"twenty":-18.566336,"median":-5.074202,"eighty":-0.570751,"marketCap":5330091},{"date":"2024-07-15","current":-0.813184,"twenty":-18.566336,"median":-5.074202,"eighty":-0.570751,"marketCap":5628047},{"date":"2024-08-02","current":-0.717515,"twenty":-19.331844,"median":-5.074202,"eighty":-0.562464,"marketCap":4965924},{"date":"2024-08-09","current":-0.569229,"twenty":-19.331844,"median":-5.074202,"eighty":-0.562464,"marketCap":3939633},{"date":"2024-08-16","current":-0.545311,"twenty":-19.331844,"median":-5.074202,"eighty":-0.558549,"marketCap":3774102},{"date":"2024-08-23","current":-0.660114,"twenty":-19.331844,"median":-5.008674,"eighty":-0.558011,"marketCap":4568650},{"date":"2024-08-30","current":-0.631413,"twenty":-19.331844,"median":-4.791826,"eighty":-0.558011,"marketCap":4370013},{"date":"2024-09-06","current":-0.617063,"twenty":-19.331844,"median":-4.539624,"eighty":-0.558011,"marketCap":4270694},{"date":"2024-09-13","current":-0.631413,"twenty":-19.331844,"median":-4.09773,"eighty":-0.558011,"marketCap":4370013},{"date":"2024-09-20","current":-0.506022,"twenty":-19.331844,"median":-4.059359,"eighty":-0.552636,"marketCap":4270694},{"date":"2024-09-27","current":-0.595973,"twenty":-19.331844,"median":-4.059359,"eighty":-0.550947,"marketCap":5029855},{"date":"2024-10-04","current":-0.595973,"twenty":-19.331844,"median":-4.059359,"eighty":-0.550947,"marketCap":5029855},{"date":"2024-10-11","current":-0.653648,"twenty":-19.331844,"median":-4.04729,"eighty":-0.550947,"marketCap":5516615},{"date":"2024-10-18","current":-0.634423,"twenty":-19.331844,"median":-2.811447,"eighty":-0.550947,"marketCap":5354362},{"date":"2024-10-25","current":-0.74016,"twenty":-19.331844,"median":-2.696359,"eighty":-0.550947,"marketCap":6246755},{"date":"2024-10-31","current":-0.70171,"twenty":-19.331844,"median":-2.614152,"eighty":-0.550947,"marketCap":5922249},{"date":"2024-11-08","current":-0.672873,"twenty":-19.430851,"median":-2.531947,"eighty":-0.550857,"marketCap":5678869},{"date":"2024-11-15","current":-0.706517,"twenty":-19.430851,"median":-2.499064,"eighty":-0.550857,"marketCap":5962812},{"date":"2024-11-22","current":-0.644036,"twenty":-19.430851,"median":-2.433299,"eighty":-0.550857,"marketCap":5435488},{"date":"2024-11-29","current":-0.624811,"twenty":-19.430851,"median":-2.433299,"eighty":-0.550857,"marketCap":5273235},{"date":"2024-12-06","current":-0.639229,"twenty":-19.430851,"median":-2.433299,"eighty":-0.550857,"marketCap":5394925},{"date":"2024-12-13","current":-0.70171,"twenty":-19.430851,"median":-2.400417,"eighty":-0.550857,"marketCap":5922249},{"date":"2024-12-20","current":-0.571942,"twenty":-19.430851,"median":-2.367534,"eighty":-0.550857,"marketCap":4827038},{"date":"2024-12-27","current":-0.749773,"twenty":-19.430851,"median":-2.367534,"eighty":-0.550857,"marketCap":6327882},{"date":"2025-01-03","current":-0.696904,"twenty":-19.430851,"median":-2.30177,"eighty":-0.550857,"marketCap":5881685},{"date":"2025-01-10","current":-0.692098,"twenty":-19.430851,"median":-2.30177,"eighty":-0.550857,"marketCap":5841122},{"date":"2025-01-17","current":-0.730548,"twenty":-19.430851,"median":-2.153798,"eighty":-0.550857,"marketCap":6165629},{"date":"2025-01-24","current":-1.150202,"twenty":-19.430851,"median":-1.874119,"eighty":-0.550857,"marketCap":6043939},{"date":"2025-01-31","current":-1.042129,"twenty":-19.430851,"median":-1.662503,"eighty":-0.550857,"marketCap":5476052},{"date":"2025-02-07","current":-1.160721,"twenty":-19.430851,"median":-1.581046,"eighty":-0.550857,"marketCap":6099215},{"date":"2025-02-14","current":-1.13637,"twenty":-19.430851,"median":-1.560974,"eighty":-0.550857,"marketCap":5971260},{"date":"2025-02-21","current":-1.038967,"twenty":-19.430851,"median":-1.560974,"eighty":-0.550857,"marketCap":5459438},{"date":"2025-02-28","current":-0.990265,"twenty":-19.430851,"median":-1.541199,"eighty":-0.550857,"marketCap":5203526},{"date":"2025-03-07","current":-0.900979,"twenty":-19.430851,"median":-1.471776,"eighty":-0.550857,"marketCap":4734356},{"date":"2025-03-14","current":-0.917213,"twenty":-19.430851,"median":-1.471776,"eighty":-0.550857,"marketCap":4819660},{"date":"2025-03-21","current":-1.211596,"twenty":-19.430851,"median":-1.471776,"eighty":-0.550857,"marketCap":6007699},{"date":"2025-03-28","current":-1.08733,"twenty":-19.430851,"median":-1.427176,"eighty":-0.550857,"marketCap":5391525},{"date":"2025-04-04","current":-1.066619,"twenty":-19.430851,"median":-1.427176,"eighty":-0.550857,"marketCap":5288829},{"date":"2025-04-11","current":-0.966947,"twenty":-19.430851,"median":-1.427176,"eighty":-0.550857,"marketCap":4794606},{"date":"2025-04-17","current":-1.004486,"twenty":-19.430851,"median":-1.424416,"eighty":-0.550857,"marketCap":4980742},{"date":"2025-04-25","current":-1.014841,"twenty":-19.430851,"median":-1.40109,"eighty":-0.550857,"marketCap":5032090},{"date":"2025-05-02","current":-1.056263,"twenty":-19.430851,"median":-1.382577,"eighty":-0.550857,"marketCap":5237481},{"date":"2025-05-09","current":-1.011735,"twenty":-19.430851,"median":-1.375382,"eighty":-0.550857,"marketCap":5016685},{"date":"2025-05-16","current":-1.004486,"twenty":-19.430851,"median":-1.366813,"eighty":-0.550857,"marketCap":4980742},{"date":"2025-05-23","current":-1.035552,"twenty":-19.430851,"median":-1.360278,"eighty":-0.550857,"marketCap":5134786},{"date":"2025-05-30","current":-1.001379,"twenty":-19.430851,"median":-1.337978,"eighty":-0.550857,"marketCap":4965338},{"date":"2025-06-06","current":-0.973316,"twenty":-19.430851,"median":-1.337978,"eighty":-0.550857,"marketCap":4826185}],"updateTime":1749395074753}}}